Deciphera Pharmaceuticals competitors and similar companiesClear all
Deciphera Pharmaceuticals's competitors and similar companies include Exelixis, Celldex Therapeutics, Blueprint Medicines, Arog Pharmaceuticals and Allakos.
 Deciphera Pharmaceuticals Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer. |  Exelixis Exelixis a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. |  Celldex Therapeutics Celldex Therapeutics (formerly known as Avant Immunotherapeutics) is developing targeted therapeutics to address devastating diseases. |  Blueprint Medicines Blueprint Medicines is a precision therapy company that invents medicines for people with cancer and blood disorders. |  Arog Pharmaceuticals Arog Pharmaceuticals is a biopharmaceutical company dedicated to improving the lives of cancer patients by developing crenolanib in indications with high unmet need. |  Allakos Allakos, a biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. | |
Founding Date | Founding Date 2003 | Founding Date 1994 | Founding Date 1983 | Founding Date 2011 | Founding Date 2010 | Founding Date 2012 |
Type | Type Public | Type Public | Type Public | Type Public | Type Private | Type Public |
Tags | ||||||
Locations | Locations Waltham, US HQ Lawrence, US | Locations Alameda, US HQ | Locations Hampton, US HQ Fall River, US Needham, US New Haven, US | Locations Cambridge, US HQ Amsterdam, NL Lugano, CH Zug, CH | Locations Plano, US HQ | Locations Redwood City, US HQ San Carlos, US |
Employees | Employees 35037% increase | Employees 61727% increase | Employees 1327% increase | Employees 49515% increase | Employees 910% decrease | Employees 967% increase |
Valuation ($) | Valuation ($) 1.1 b | Valuation ($) 6.1 b | Valuation ($) 2 b | Valuation ($) 2.5 b | Valuation ($) N/A | Valuation ($) 392.8 m |
Twitter followers | Twitter followers 750 | Twitter followers 5.8 k | Twitter followers N/A | Twitter followers 2.7 k | Twitter followers N/A | Twitter followers N/A |
Number of tweets (last 30 days) | Number of tweets (last 30 days) 5 | Number of tweets (last 30 days) 10 | Number of tweets (last 30 days) N/A | Number of tweets (last 30 days) 12 | Number of tweets (last 30 days) N/A | Number of tweets (last 30 days) N/A |
Average likes per tweet (last 30 days) | Average likes per tweet (last 30 days) 5.2 | Average likes per tweet (last 30 days) 1.5 | Average likes per tweet (last 30 days) N/A | Average likes per tweet (last 30 days) 4.8 | Average likes per tweet (last 30 days) N/A | Average likes per tweet (last 30 days) N/A |
Percentage of tweets with engagement (last 30 days) | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) 60% | Percentage of tweets with engagement (last 30 days) N/A | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) N/A | Percentage of tweets with engagement (last 30 days) N/A |
Employee Rating | Employee Rating 3.7 | Employee Rating 2.7 | Employee Rating 3.9 | Employee Rating 4.2 | Employee Rating 1.8 | Employee Rating 4.4 |
Financial | ||||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $1.6b (FY, 2022) | Revenue (est.) $2.4m (FY, 2022) | Revenue (est.) $204m (FY, 2022) | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods $57.9m (FY, 2022) | Cost of goods $100k (FY, 2022) | Cost of goods $17.8m (FY, 2022) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $1.6b (FY, 2022) | Gross profit $2.3m (FY, 2022) | Gross profit $186.2m (FY, 2022) | Gross profit N/A | Gross profit N/A |
Net income | Net income ($25.9m) (FY, 2016) | Net income $182.3m (FY, 2022) | Net income ($113m) (FY, 2022) | Net income ($557.5m) (FY, 2022) | Net income ($11.6m) (FY, 2017) | Net income ($320m) (FY, 2022) |
Funding | ||||||
Total funding raised | Total funding raised $ 714m | Total funding raised N/A | Total funding raised $ 2m | Total funding raised $ 1.7b | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View company profiles
Exelixis
HQ
Alameda, US
Employees
617↑ 27% increase
Exelixis a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer.
View companyCelldex Therapeutics
HQ
Hampton, US
Employees
132↑ 7% increase
Celldex Therapeutics (formerly known as Avant Immunotherapeutics) is developing targeted therapeutics to address devastating diseases.
View companyBlueprint Medicines
HQ
Cambridge, US
Employees
495↑ 15% increase
Blueprint Medicines is a precision therapy company that invents medicines for people with cancer and blood disorders.
View companyArog Pharmaceuticals
HQ
Plano, US
Employees
9↓ 10% decrease
Arog Pharmaceuticals is a biopharmaceutical company dedicated to improving the lives of cancer patients by developing crenolanib in indications with high unmet need.
View company